Walleye Capital
MDGL icon

Walleye Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Walleye Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
+400
New +$205K ﹤0.01% 3450
2026
Q1 		– Sell
-700
Closed -$408K – 4729
2025
Q4 		$408K Sell
700
-200
-22% -$102K ﹤0.01% 3084
2025
Q3 		$413K Buy
900
+500
+125% +$187K ﹤0.01% 2775
2025
Q2 		$121K Sell
400
-300
-43% -$89.4K ﹤0.01% 3676
2025
Q1 		$232K Sell
700
-400
-36% -$131K ﹤0.01% 3157
2024
Q4 		$339K Buy
+1,100
New +$309K ﹤0.01% 3322
2024
Q3 		– Sell
-900
Closed -$252K – 5645
2024
Q2 		$252K Buy
900
+400
+80% +$95.2K ﹤0.01% 4124
2024
Q1 		$134K Buy
+500
New +$118K ﹤0.01% 4220
2023
Q2 		– Sell
-400
Closed -$96.9K – 4651
2023
Q1 		$96.9K Buy
+400
New +$109K ﹤0.01% 2947
2020
Q1 		– Sell
-1,600
Closed -$146K – 1370
2019
Q4 		$146K Sell
1,600
-3,000
-65% -$291K 0.01% 1250
2019
Q3 		$397K Sell
4,600
-14,600
-76% -$1.37M 0.02% 859
2019
Q2 		$2.01M Buy
19,200
+18,500
+2,643% +$1.98M 0.22% 90
2019
Q1 		$88K Buy
+700
New +$87K 0.01% 1078

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's MDGL Position: Q2 2026 in Review

Walleye Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 13,227 shares — an estimated $6.78M sold.

Walleye Capital first reported a position in MDGL in Q4 2019 and held it in 6 quarters. The position peaked at $6.92M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Walleye Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 13,227 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $6.78M.
  • Walleye Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Walleye Capital's Madrigal Pharmaceuticals position peaked at $6.92M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.